A phase I trial of intraperitoneal nab-paclitaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity.
Publication Title
Cancer chemotherapy and pharmacology
Document Type
Article
Publication Date
3-1-2019
Keywords
Intraperitoneal chemotherapy; Nab-paclitaxel; Peritoneal carcinomatosis; ovarian cancer; Pharmacologic advantage
Abstract
PURPOSE: To evaluate intraperitoneal (IP) nab-paclitaxel in patients with advanced malignancies that are primarily confined to the peritoneal cavity in a phase I trial.
METHODS: Using a 3 + 3 dose escalation of IP nab-paclitaxel on days 1, 8, and 15 of a 28-day cycle, we evaluated six dose levels (35-175 mg/m
RESULTS: There were no dose-limiting toxicities (DLTs) in cohorts 1-3. There was a DLT in one of six patients in cohort 4 (112.5 mg/m
CONCLUSIONS: Weekly IP nab-paclitaxel has a favorable toxicity profile, a significant pharmacologic advantage, and promising clinical activity.
CLINICAL TRIAL REGISTRATION: NCT00825201.
Clinical Institute
Cancer
Specialty/Research Institute
Oncology
